Eric A Murphy, Ph.D. is Co-Founder and Chief Scientific Officer of the Fount Therapeutics group of companies. Eric has developed significant expertise in drug discovery and development over the last 20 years in academic, biotechnology, and pharmaceutical settings. Most recently he served as Global Head of Oncology R&D Strategy and External Innovations at Crown Biosciences, Inc. prior to its acquisition by JSR Corporation. While at Samumed, LLC, he established the Discovery Biology group and contributed to research and early development of multiple molecules in clinical trials including osteoarthritis (Ph III), alopecia (Ph II), tendinopathy (Ph I), psoriasis (Ph I), scleroderma (Ph I), and oncology (Ph I). As a Research Investigator at Novartis – GNF, Eric contributed to discovery pharmacology/translational research and early development of 6 clinical oncology therapeutics targeting the MAPK pathway, WNT pathway, and oncogenic RTK signaling. His work at the UCSD Moores Cancer Center lead to multiple high tier publications in the fields of anti-angiogenesis, nanomedicine, and RAF kinase biology/drug discovery resulting in co-founding Kinagen Inc. with Dr. David Cheresh. Eric currently serves as a Board Member at Fount Therapeutics LLC and Kinnate Biopharma, Inc. as well as a Strategic/Scientific Advisor for PALtown/Colontown (patient advocacy) and Cell Response Inc. He completed his postdoctoral fellowship at The Scripps Research Institute in cancer biology and studies in Biochemistry at UC Davis (B.S.) and UC Irvine (Ph.D).